Fidelity National Financial, Inc. (FNF) Analysts See $0.60 EPS; Sunesis Pharmaceuticals, Inc. (SNSS) Had 2 Analysts Last Week

January 22, 2018 - By Marie Mckinney

Analysts expect Fidelity National Financial, Inc. (NYSE:FNF) to report $0.60 EPS on February, 7.They anticipate $0.11 EPS change or 15.49% from last quarter’s $0.71 EPS. FNF’s profit would be $163.89M giving it 17.29 P/E if the $0.60 EPS is correct. After having $0.71 EPS previously, Fidelity National Financial, Inc.’s analysts see -15.49% EPS growth. The stock increased 0.36% or $0.15 during the last trading session, reaching $41.5. About 1.28 million shares traded. Fidelity National Financial, Inc. (NYSE:FNF) has risen 25.97% since January 22, 2017 and is uptrending. It has outperformed by 9.27% the S&P500.

Among 5 analysts covering Sunesis Pharmaceuticals (NASDAQ:SNSS), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. Sunesis Pharmaceuticals had 11 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was downgraded by TH Capital on Friday, July 24 to “Sell”. The firm earned “Market Perform” rating on Friday, July 24 by Cowen & Co. The stock has “Buy” rating by Wells Fargo on Monday, December 11. Oppenheimer initiated the shares of SNSS in report on Monday, November 20 with “Buy” rating. The rating was downgraded by Cantor Fitzgerald on Friday, July 24 to “Hold”. As per Thursday, December 14, the company rating was initiated by Oppenheimer. On Friday, July 29 the stock rating was upgraded by Wells Fargo to “Outperform”. The stock of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has “Market Perform” rating given on Tuesday, December 5 by Wells Fargo. The rating was maintained by Cantor Fitzgerald on Tuesday, July 18 with “Hold”. The firm has “Hold” rating given on Thursday, July 27 by Cantor Fitzgerald. See Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) latest ratings:

14/12/2017 Broker: Oppenheimer Rating: Buy New Target: $7.0 Initiate
11/12/2017 Broker: Wells Fargo Rating: Buy Upgrade
05/12/2017 Broker: Wells Fargo Old Rating: Outperform New Rating: Market Perform Downgrade
20/11/2017 Broker: Oppenheimer Rating: Buy New Target: $7.0 Initiate
02/11/2017 Broker: Cowen & Co Rating: Hold
27/07/2017 Broker: Cantor Fitzgerald Rating: Hold New Target: $3.0000 Maintain

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company has market cap of $145.21 million. The firm is developing vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia . It currently has negative earnings. It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML.

The stock increased 1.68% or $0.07 during the last trading session, reaching $4.24. About 43,287 shares traded. Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has risen 8.33% since January 22, 2017 and is uptrending. It has underperformed by 8.37% the S&P500.

Fidelity National Financial, Inc., together with its subsidiaries, provides title insurance, technology, and transaction services to the real estate and mortgage industries in the United States. The company has market cap of $11.34 billion. It offers title insurance, escrow, and other title related services, including collection and trust activities, trustee sales guarantees, recordings and conveyances, and home warranty insurance. It has a 17.79 P/E ratio. The firm also offers information used by title insurance underwriters, title agents, and closing attorneys to underwrite title insurance policies for real property sales and transfer.

Among 8 analysts covering Fidelity National Financial (NYSE:FNF), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Fidelity National Financial had 23 analyst reports since August 3, 2015 according to SRatingsIntel. The company was maintained on Thursday, December 21 by Keefe Bruyette & Woods. The stock of Fidelity National Financial, Inc. (NYSE:FNF) earned “Buy” rating by Piper Jaffray on Monday, December 18. Piper Jaffray maintained the stock with “Overweight” rating in Friday, September 25 report. The firm earned “Buy” rating on Thursday, July 20 by Piper Jaffray. The stock of Fidelity National Financial, Inc. (NYSE:FNF) has “Buy” rating given on Monday, January 25 by Monness Crespi & Hardt. Piper Jaffray maintained Fidelity National Financial, Inc. (NYSE:FNF) on Monday, October 16 with “Buy” rating. Barclays Capital maintained Fidelity National Financial, Inc. (NYSE:FNF) rating on Friday, October 27. Barclays Capital has “Overweight” rating and $41 target. The stock of Fidelity National Financial, Inc. (NYSE:FNF) earned “Hold” rating by Keefe Bruyette & Woods on Friday, September 8. The rating was downgraded by Wood on Monday, July 18 to “Market Perform”. The firm has “Overweight” rating by Barclays Capital given on Friday, February 12.

Investors sentiment increased to 1.21 in Q3 2017. Its up 0.17, from 1.04 in 2017Q2. It improved, as 23 investors sold Fidelity National Financial, Inc. shares while 107 reduced holdings. 57 funds opened positions while 100 raised stakes. 215.64 million shares or 0.11% less from 215.86 million shares in 2017Q2 were reported. Raymond James Associate holds 0.02% of its portfolio in Fidelity National Financial, Inc. (NYSE:FNF) for 204,595 shares. Keybank National Association Oh holds 0% or 11,722 shares in its portfolio. Swift Run Capital Mgmt Ltd Liability Corp accumulated 66,580 shares. Hudock Capital Ltd holds 0.01% or 445 shares in its portfolio. Ameriprise Finance has 294,206 shares for 0.01% of their portfolio. Parkside Financial Bank & Tru holds 0% or 32 shares. Commonwealth Equity Services Inc stated it has 5,229 shares. Zwj Invest Counsel invested 0.02% of its portfolio in Fidelity National Financial, Inc. (NYSE:FNF). Penn Cap Management, Pennsylvania-based fund reported 64,776 shares. Usa Fincl Portformulas has invested 0.19% in Fidelity National Financial, Inc. (NYSE:FNF). Archon Prns Ltd Liability Com, a New York-based fund reported 36,200 shares. Park National Corp Oh holds 5,210 shares or 0.01% of its portfolio. 220,500 are held by Andra Ap. 121,000 were accumulated by Maltese Capital Mgmt Limited Liability Company. Bluemountain Cap Ltd Company has 43,264 shares.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>